Aptahem » Erika Medin

Second cohort in Aptahem’s FIH study performed and approved by the ethics committee

2023-02-10

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the second dose cohort in the clinical First in Human (FIH) study in healthy volunteers has been performed...

BioStock-artikel: Aptahem hoppas nå flera milstolpar under 2023

2023-01-27

BioStock publicerade den 27 januari 2023 en artikel om Aptahem, som återges nedan i sin helhet. Aptahem inledde under 2022 sin första kliniska studie med läkemedelskandidaten Apta-1, en akutbehandling mot sepsis och livshotande inflammatoriska tillstånd. För BioStock berättar vd...

First cohort dosed in Aptahem’s FIH study

2022-12-29

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first cohort of healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study....

Newsletter December 2022

2022-12-22

CEO comments The year 2022 can be summarized in great progress for Aptahem. We have taken several steps towards to goal to develop our lead candidate Apta-1 for acute, inflammatory diseases such as sepsis. The year was focused on...

Aptahem AB (publ) meddelar sista dag för handel med BTA

2022-12-16

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

First subjects dosed in Aptahem’s FIH study

2022-12-14

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers (HV) have been dosed in the clinical First in Human (FIH) study. The first...

Aptahem AB (publ) offentliggör utfall i företrädesemission

2022-12-06

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA...

First subjects screened in Aptahem’s FIH study with Apta-1

2022-12-05

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases such as sepsis, announces today that the first healthy volunteers have been screened for inclusion in the clinical First in Human (FIH) study with...

Aptahem reports added positive and significant biological effect in an extended Corona virus-induced acute lung injury model treated with Apta-1

2022-12-01

Aptahem can today announce that the Toronto team, in extended studies in addition to previously reported positive preliminary data, has concluded significant positive effects in a severe Corona virus induced Acute Lung Injury model with Apta-1 treatment. The preliminary...

Aptahem’s CEO interviewed during the Biotechgate conference

2022-12-01

Mikael Lindstam, CEO at Aptahem, was interviewed during the Biotechgate digital partnering conference. In the video he describes the development process with the company’s lead candidate Apta-1, from discovery, through manufacturing and preclinical studies up to clinical phase. The...